PGV001, a personalized cancer vaccine, induced immune responses across various cancer types like breast and urothelial cancer ...

But a lack of natural models to study these quiescent stages has led to gaps in scientists' understanding ... which helps the ...

Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...

Your immune system protects you, but sometimes it overreacts. Learn how to recognize the signs and regain balance.

(RTTNews) - Greenwich LifeSciences, Inc. (GLSI) Wednesday reported preliminary positive immune response data from FLAMINGO-01 Phase 3 study evaluating GLSI-100, an immunotherapy to prevent breast ...

Aura Biosciences (AURA) announced data from a completed Phase 1 window of opportunity trial of bel-sar in patients with NMIBC. These data were ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved ...

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We continue to be encouraged by the data emerging from the Phase 2 VacSYn trial of ACI-7104.056 active immunotherapy in early Parkinson’s ...

The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA ...

The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types ...